Pelago Bioscience acquires RG Discovery, forming an integrated drug discovery partner covering biology and chemistry
Pelago Bioscience, a contract research organization (CRO) specializing in drug discovery and renowned for its cutting-edge cell target engagement assays, is pleased to announce the acquisition of RG Discovery, adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery.
By combining Pelago Bioscience’s biology-focused capabilities with RG Discovery’s chemical expertise, the expanded platform will enable drug discovery teams to accelerate decision-making, harmonize workflows, and advance programs more efficiently, from hit identification to lead compound optimization.
Drug discovery increasingly requires seamless integration between chemistry and biology,” said Michael Dabrowski, CEO of Pelago Bioscience. “By integrating RG Discovery into Pelago Bioscience, we can offer our customers a single scientific partner capable of designing and synthesizing compounds, evaluating their interaction with the target in living cells, and rapidly injecting that information into the next design cycle. This combination strengthens our ability to help our customers advance their programs faster and with greater confidence.
Pelago Bioscience’s proprietary platform, based on the CETSA® (Cellular Thermal Shift Assay), provides direct insights into how compounds interact with their targets in living cells. This data can now be directly reused in RG Discovery’s next compound design cycle, a seamless chemistry-to-biology loop that no CRO specializing in pure chemistry or biology can offer. This alliance thus closes the loop between compound design, synthesis, and direct in vivo target interaction, putting it at the forefront of the market and eliminating the inter-vendor handoffs that slow down programs between the discovery of a promising compound and the identification of a lead candidate.
Founded in 2011 by former AstraZeneca scientists, RG Discovery has built a reputation for solving complex chemical challenges for biotechnology and pharmaceutical companies. The company employs approximately 40 scientists and operates from Medicon Village in Lund, Sweden, where its facilities include a comprehensive chemical and analytical infrastructure supporting a wide range of drug discovery activities.
RG Discovery has always been committed to helping its customers solve complex scientific problems through close collaboration and deep technical expertise,” says Johan Evenäs, CEO and co-founder of RG Discovery. “By joining forces with Pelago Bioscience, we can expand our impact by combining world-class chemistry with cutting-edge target engagement science. We are excited about the opportunities this creates for both our customers and our team.
About Pelago Bioscience
Pelago Bioscience is a contract research organization (CRO) specializing in drug discovery, particularly target engagement and validation, using its proprietary CETSA® technology platform. By directly measuring drug-target interactions in living cells and tissues, Pelago Bioscience helps pharmaceutical and biotechnology companies make more informed decisions throughout the drug discovery and development process. The company is headquartered in Stockholm, Sweden.
About RG Discovery
RG Discovery is an integrated CRO specializing in drug discovery, headquartered in Lund, Sweden. The company provides medicinal chemistry, peptide chemistry, custom synthesis, ADME, bioanalytical, and other discovery-related services to biotechnology and pharmaceutical clients worldwide.
Source link: https://www.businesswire.com/
